PIK3CA and metastatic neoplasm: Chemotherapy treatment in the setting of neoadjuvant/adjuvant treatment for early-stage disease or metastatic disease was not associated with the prevalence of ESR1 or PIK3CA mutations in cfDNA (Table 3).